Displayed at 95 Horatio Street, NY, PWSC argues that stuttering fosters deep listening and collaboration, aiming to transform social reality...
      Speech and language impairments are core features of the neurodevelopmental genetic condition Kleefstra syndrome. The speech, language and cognitive profile...
        MEDIA RELEASE Melbourne, 19 January 2024 — Redenlab, a leader in innovative healthcare solutions, ispleased to announce a groundbreaking study...
          Exposing healthy adults to extended periods of wakefulness is known to induce changes in psychomotor functioning. The effect of fatigue...
            While speech biomarkers of disease have attracted increased interest in recent years, a challenge is that features derived from signal...
              Smart devices are widely available and capable of quickly recording and uploading speech segments for health-related analysis. The switch from...
                Self-reported ratings of stuttering have great potential utility for large-scale data collection, where cost and time preclude in-depth assessment by...
                  Stuttering is a speech disorder characterised by the prolongation or repetition of speech words, sounds or syllables, together with interruptions...
                    Speech disorders impacting children have debilitating impacts on educational, social and later employment outcomes. There are limited therapeutic options for...
                      Spinocerebellar ataxia Type 1 (SCA1) is a dominantly inherited neurodegenerative disease resulting in balance, speech, thinking and coordination difficulties. SCA1...
                        Friedreich ataxia (FA) is a progressive, genetically inherited multisystem disease that affects children and adults. FA leads to significant changes...
                          Friedreich ataxia (FA) is an inherited, multisystem neurodegenerative disease that results in profound changes to speech, swallowing, balance, walking, cardiac...
                            Redenlab, a leading provider of innovative solutions in the field of pediatric and neurodevelopment communication, proudly announces that Professor Angela...
                              Dentatorubral-pallidoluysian atrophy (DRPLA) is a rare progressive brain disorder that can impact children and adults. In children, DRPLA can lead...
                                Redenlab are thrilled to announce that Dr. Peter Gibilisco has joined Redenlab's advisory board. As a consumer advisor with profound...
                                  MEDIA RELEASERedenlab, a leading techbio company, proudly announces its recent feature on the highly acclaimed Huberman Podcast. The podcast episode...
                                    Redenlab are partnering with Monash university, University of Melbourne, Eastern Health, and Invicta to deliver this world-first collaboration investigating neurofilament...
                                      Angela Morgan, PhD, is a National Health and Medical Research Council Elizabeth Blackburn Fellow and leads the Speech and Language...
                                        L16HTHOUSE is a research trial testing an experimental medication for treating speech, motor, learning, and other developmental delays in children...
                                          Ataxia telangiectasia (A-T) is a rare inherited condition that affects the nervous and immune systems. A-T typically impacts movement, vision...
                                            Speech and language development is a complex, multifactorial process driven by the individual’s ability to process and formulate communication. These...
                                              Scientists are turning to retinas as a potential screening target for early signs of Alzheimer's, an incurable neurodegenerative disease that...
                                                Primary Progressive Aphasia is a type of young onset dementia that is characterised by language impairment. Measuring disease progression and...
                                                  Stereotypical depictions of speech in cannabis users often suggest slow, laboured output, yet objective evidence supporting this assumption is extremely...
                                                    Speech is a cardinal and important feature of ataxia. We have put together a comprehensive description of dysarthria in spinocerebellar...
                                                      The paper describes the outcomes from a clinical trial for Friedreich ataxia (the most common hereditary ataxia impacting walking, talking,...
                                                        Critically ill patients, like those in intensive care units, are a highly complex and varied group. Many critically ill patients...
                                                          Join World BI for its 23rd rebranded edition of the Digital Health Innovation in Clinical Trials, Drug Development and Mobile...
                                                            Curebase, a company dedicated to democratizing clinical trials through a decentralized model is announcing its partnership with Redenlab, a global...
                                                              The 4th Annual Kabuki Syndrome Foundation Research Conference to be held virtually on Friday, November 4, 2022. The Annual Conference...
                                                                Join World BI and Redenlab for the 20th Clinical Trials Innovation Programme, to learn from experts in the drug development...
                                                                  MEDIA RELEASEFRIDAY 15 JULY 2022 As many as 70% of people who experience stuttering have a family member who also...

                                                                    Dr Garcia joins the Redenlab science team to drive its language analytics pipeline for cognitive-linguistic disorders like fronto-temporal dementia.

                                                                      Redenlab’s latest iOS application provides state of the art audio capture, storage and analysis of speech and language data for monitoring brain health.

                                                                        Redenlab is contributing to a study sponsored by the Australian Department of Defence and The University of Melbourne on speech biometrics and decision making in submariners

                                                                          Dr Amir Lahav hired as Chief of Digital Health and Strategy. He is a clinical neuroscientist and a leading innovator in digital health with a special focus on developing and validating novel biomarkers and AI-driven technology for remote monitoring of patients with neurodegenerative diseases.

                                                                            Dr Geoff Stuart joins the Redenlab analytics team as Statistics Director. Geoff will be running the company’s clinical trials statistics program and data analytics development. He brings expertise in mathematical statistics and a background in experimental psychology.

                                                                              Redenlab are part of a successful consortium securing funding for training a new cohort of early career researchers in understanding key issues in optimal ageing (including environmental, social and economic factors that underlie health and independence in ageing).

                                                                                Redenlab Inc. are pleased to announce securing clinical trial in Cyclic Vomiting Syndrome with a Top 10 pharma company. Redenlab are providing audio capture and analytics for a Phase 1b clinical trial. Conducted in sites across the USA, the study will investigate the long-term efficacy of a treatment designed to ameliorate the impact of this rare and debilitating disease.

                                                                                  Professor Angela Morgan has been recognised for her outstanding leadership in advancing the diagnosis, prognosis and management of childhood speech disorders.

                                                                                    Redenlab CSO, Adam Vogel, will be presenting at the upcoming ERN-RND joint webinar with the European Acadamy of Neurology and ERN EURO-NMD: Speech as a biomarker in Ataxia: What can it tell us & how should we use it?

                                                                                      SpeechATAXIA is a multi-language, multi-national, multi-ataxia consortia designed to measure communication change over time.

                                                                                        Redenlab are proud to support an upcoming randomized parallel group, placebo-controlled, dose-escalation clinical trial in Ataxia Telangiectasia

                                                                                          Welcome Dr Noffs. Gustavo brings a wealth of clinical and research experience to the team, making contributions to tech development and science promotion, with a focus on his specialties of Parkinson’s disease and Multiple Sclerosis.

                                                                                            Redenlab Inc. are excited to announce securing another clinical trial in Friedreich ataxia. Redenlab are providing speech analytics for a long-term open label extension clinical trial. Conducted in 8 sites across the USA over 2 years, the study will investigate the long-term efficacy of a treatment designed to ameliorate the debilitating impact of this fatal disease. For the study, Redenlab will provide advanced speech recording and analysis solutions.

                                                                                              Redenlab Inc, the speech neuroscience company delivering insights in communication testing, announces that it has been selected by USA and...

                                                                                                Redenlab are glad to be supporting Larimar Therapeutics Inc. Phase 1 SAD clinical trial is a double-blind, placebo-controlled, randomized clinical trial to assess the safety of subcutaneously administered CTI-1601 versus placebo in adult subjects with Friedreich Ataxia.

                                                                                                  Redenlab are proud to be supporting PTC Therapeutics, Inc. Global Phase 3 Clinical Trial to Evaluate Vatiquinone in Friedreich Ataxia.

                                                                                                    Learn more about the platforms and applications that Redenlab use for software development, documentation, and quality management that is in-line with standards such as FDA 21 CFR Part 22.

                                                                                                      We are excited to announce that Redenlab Speech Scientists ranked top 1 AND 2 in the world for dysarthria (most common neuromuscular speech disorder)!

                                                                                                        Redenlab has entered into a 5 year collaboration with investigators from North and South America, Australia and Europe to investigate the underlying neural mechanisms of Friedreich ataxia. The study is supported by the Friedreich's Ataxia Research Alliance (FARA) and pharmaceutical industry partners.

                                                                                                          Describing the relationship between disease severity and speech metrics, through listener-based and objective acoustic analysis.

                                                                                                            In our new study, published in the Journal of Acoustical Society of America, we tested reliability, stability, and sensitivity to change in vowel measurements.